513 related articles for article (PubMed ID: 34052813)
1. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
Sun Y; Tisdale RK; Kilduff TS
Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
[TBL] [Abstract][Full Text] [Related]
2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of hypocretin receptor-2 signaling in dopaminergic neurons induces hyperarousal and enhanced cognition but impaired inhibitory control.
Bandarabadi M; Li S; Aeschlimann L; Colombo G; Tzanoulinou S; Tafti M; Becchetti A; Boutrel B; Vassalli A
Mol Psychiatry; 2024 Feb; 29(2):327-341. PubMed ID: 38123729
[TBL] [Abstract][Full Text] [Related]
4. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.
Mieda M; Sakurai T
CNS Drugs; 2013 Feb; 27(2):83-90. PubMed ID: 23359095
[TBL] [Abstract][Full Text] [Related]
5. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
6. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
[TBL] [Abstract][Full Text] [Related]
7. The present and future of synthetic orexin receptor agonists.
Saitoh T; Sakurai T
Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
[TBL] [Abstract][Full Text] [Related]
8. Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area.
Mavanji V; Perez-Leighton CE; Kotz CM; Billington CJ; Parthasarathy S; Sinton CM; Teske JA
Sleep; 2015 Sep; 38(9):1361-70. PubMed ID: 25845696
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
10. Excitation of Cortical nNOS/NK1R Neurons by Hypocretin 1 is Independent of Sleep Homeostasis.
Williams RH; Black SW; Thomas AM; Piquet J; Cauli B; Kilduff TS
Cereb Cortex; 2019 Mar; 29(3):1090-1108. PubMed ID: 29462275
[TBL] [Abstract][Full Text] [Related]
11. The orexin story, sleep and sleep disturbances.
Pizza F; Barateau L; Dauvilliers Y; Plazzi G
J Sleep Res; 2022 Aug; 31(4):e13665. PubMed ID: 35698789
[TBL] [Abstract][Full Text] [Related]
12. The roles of orexins in sleep/wake regulation.
Mieda M
Neurosci Res; 2017 May; 118():56-65. PubMed ID: 28526554
[TBL] [Abstract][Full Text] [Related]
13. Hypocretin and its emerging role as a target for treatment of sleep disorders.
Cao M; Guilleminault C
Curr Neurol Neurosci Rep; 2011 Apr; 11(2):227-34. PubMed ID: 21170610
[TBL] [Abstract][Full Text] [Related]
14. Hypocretin antagonists in insomnia treatment and beyond.
Ruoff C; Cao M; Guilleminault C
Curr Pharm Des; 2011; 17(15):1476-82. PubMed ID: 21476951
[TBL] [Abstract][Full Text] [Related]
15. The role of the hypocretinergic system in the integration of networks that dictate the states of arousal.
Winsky-Sommerer R; Boutrel B; De Lecea L
Drug News Perspect; 2003 Oct; 16(8):504-12. PubMed ID: 14668948
[TBL] [Abstract][Full Text] [Related]
16. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.
Roecker AJ; Cox CD; Coleman PJ
J Med Chem; 2016 Jan; 59(2):504-30. PubMed ID: 26317591
[TBL] [Abstract][Full Text] [Related]
17. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
18. The role of the orexin system in stress response.
Sargin D
Neuropharmacology; 2019 Aug; 154():68-78. PubMed ID: 30266600
[TBL] [Abstract][Full Text] [Related]
19. Toward the Mysteries of Sleep.
Yanagisawa M
Keio J Med; 2019; 68(1):27. PubMed ID: 30905886
[TBL] [Abstract][Full Text] [Related]
20. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat.
Gerashchenko D; Kohls MD; Greco M; Waleh NS; Salin-Pascual R; Kilduff TS; Lappi DA; Shiromani PJ
J Neurosci; 2001 Sep; 21(18):7273-83. PubMed ID: 11549737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
